GTx (GTXI) submits a complete response letter to the FDA regarding the full clinical hold on prostate cancer treatment Capesaris. The company says it plans to develop Capesaris as a secondary hormonal therapy for advanced prostate cancer at doses lower than those previously tested.
GTx (GTXI) submits a complete response letter to the FDA regarding the full clinical hold on...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs